Quick Order Cart

Cat. No. ARG36390

IL3 Knockout Lovo Polyclonal Cells

  • Product Type:

    Polyclonal Cell Population

  • Species:

    Homo sapiens (Human)

  • Tissue Source:

    Large intestine (colon)

  • Disease:

    Adenocarcinoma

The IL3 Knockout LoVo Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting IL3 in the LoVo human colorectal adenocarcinoma line. This model disrupts interleukin-3 (IL3) function, abrogating downstream JAK2/STAT5 and PI3K/AKT signaling, and provides a tool to study its role in metastatic colorectal cancer, inflammatory modulation, and cytokine-driven proliferation. Applications include phospho-protein analysis, proliferation assays, and co-culture migration studies to explore IL3-dependent mechanisms in cancer signaling, tumor microenvironment, and drug resistance. The polyclonal knockout format ensures unbiased functional assessments without clonal selection.

Inquire Now

In stock

Ships next business day


Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice


Disclaimer:

For Research Use Only

  • Characteristics

    Host Cell

    LoVo

    Sex of Donor

    Male

    Age

    56 years

    Gene Name

    IL3

    Gene Identifier

    NCBI Gene ID 3562

    Morphology

    Epithelial-like

    Growth Mode

    Adherent

    Storage

    Liquid nitrogen (LN2)

  • Culture Conditions

    Growth medium

    Ham's F-12K

    Supplement(s)

    10% Fetal Bovine Serum, 1% Penicillin-Streptomycin Solution

    Temperature

    37°C

    Atmosphere

    5% CO₂

  • Quality Control

    Sterility testing

    The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

    Mycoplasma testing

    Negative for mycoplasma through PCR analysis

  • Disclaimer

    Intended Use

    This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.

    Disclaimer

    Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

    By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

    This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

The IL3 Knockout LoVo Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population in which the IL3 gene has been disrupted within the LoVo human colorectal adenocarcinoma cell line. This polyclonal format provides a heterogeneous loss-of-function model, enabling robust functional genomic studies without clonal selection artifacts. These cells are ideally suited for investigating interleukin-3 (IL3)-dependent mechanisms in a metastatic colorectal cancer context.

LoVo cells originated from a supraclavicular lymph node metastasis of colorectal adenocarcinoma and harbor oncogenic mutations in APC and KRAS, leading to constitutive activation of Wnt and MAPK pathways. As a well-characterized model for metastatic colorectal cancer, this cell line recapitulates key features of tumor progression and drug resistance. The IL3 knockout in this background permits dissection of cytokine cross-talk with established oncogenic drivers.

IL3 is a hematopoietic growth factor that signals through a heterodimeric receptor (IL3RA/CSF2RB) to activate JAK2, which phosphorylates STAT5 and initiates PI3K/AKT and RAS/MAPK cascades. Downstream effectors include Bcl-xL, Cyclin D1, and ERK, promoting proliferation and survival. Knockout of IL3 abrogates these signals, eliminating cytokine-driven activation of STAT5, AKT, and ERK, thereby impairing downstream transcriptional programs.

In the LoVo metastatic colorectal cancer model, autocrine or paracrine IL3 signaling may influence tumor cell growth, apoptosis resistance, or microenvironment interactions. Although IL3 is not a primary colorectal oncogene, its receptor components can be expressed in tumor and stromal cells. Disrupting IL3 enables investigation of its potential contributions to inflammatory modulation and immune cell crosstalk within the tumor milieu.

Typical applications include western blotting for phospho-STAT5 and phospho-AKT to verify pathway inhibition, RT-qPCR and ELISA to quantify IL3 and target gene expression, and cell proliferation or apoptosis assays to assess functional consequences. Co-culture migration and invasion studies further explore paracrine effects. This model supports research in cytokine biology, tumor microenvironment, drug resistance, and functional genomics. For more information, contact Ascent Research.

Reset Password

    Reach Us Questions? Click Me Here!

    Fill out the form below and a member of our team will contact you shortly!

    *Required field



      Reach Us

      Fill out the form below and a member of our team will contact you shortly!

      *Required field

      Product Inquiry (Optional)